... to our preclinical programs partially offset by lower clinical trial and manufacturing expenses for our SB-728-T HIV/AIDS program. General and administrative expenses were $3.1 million for the second quarter of 2013 and $2.7 million for the same ...
http://www.freshnews.com/news/825073/sangamo-biosciences-reports-second-quarter-2013-financial-results
http://www.freshnews.com/news/825073/sangamo-biosciences-reports-second-quarter-2013-financial-results
